nct_id: NCT06084936
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-10-16'
study_start_date: '2023-10-22'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Tocilizumab'
  - drug_name: 'Drug: Glofitamab'
  - drug_name: 'Drug: Bendamustine'
  - drug_name: 'Drug: Obinutuzumab'
  - drug_name: 'Drug: Lenalidomide'
  - drug_name: 'Drug: Rituximab'
long_title: A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab
  as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory
  Mantle Cell Lymphoma
last_updated: '2025-11-05'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Hoffmann-La Roche
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 182
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Life expectancy at least 12 weeks'
- '* Histologically-confirmed MCL, with documentation of either overexpression of
  cyclin D1 or the presence of t(11:14)'
- '* Relapsed (disease progression after the last treatment regimen) or refractory
  (failure to achieve a partial or complete response from the last treatment regimen)
  disease'
- '* At least 1 line of prior systemic therapy including a BTK inhibitor and additional
  systemic therapy option'
- '* Confirmed availability of tumor tissue, unless deemed unsafe per investigator
  assessment'
- '* At least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion,
  or one bi-dimensionally measurable (at least 1 cm) extranodal lesion, as measured
  on CT scan'
- '* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2'
- '* Negative HIV test at screening'
- '* Adequate hematological function'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Pregnancy or breastfeeding, or intention of becoming pregnant during
  the study or within 3 months after the final dose of tocilizumab, 2 months after
  the final dose of glofitamab, whichever is longer
- Exclude - * Leukemic, non-nodal MCL
- Exclude - * History of severe allergic or anaphylactic reactions to humanized or
  murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or
  known sensitivity or allergy to murine products
- Exclude - * Contraindication to obinutuzumab or rituximab, and either bendamustine
  or lenalidomide
- Exclude - * Prior treatment with glofitamab or other bispecific antibodies targeting
  both CD20 and CD3
- Exclude - * Prior treatment with CAR-T cell therapy
- Exclude - * Treatment with systemic therapy or BTK inhibitors, or any investigational
  agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever
  is shorter) prior to first study treatment
- Exclude - * Primary or secondary CNS lymphoma at the time of recruitment or history
  of CNS lymphoma
- Exclude - * Current or history of CNS disease, such as stroke, epilepisy, CNS vasculitis,
  or neurodegenerative disease
- Exclude - * History of other malignancy that could affect compliance with the protocol
  or interpretation of results
- Exclude - * Significant or extensive cardiovascular disease
- Exclude - * Known active bacterial, viral, fungal, mycobacterial, parasitic, or
  other infection at study enrollment or any major episode of infection within 4 weeks
  prior to the first study treatment
- Exclude - * Suspected or latent tuberculosis
- Exclude - * Positive test for hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Exclude - * Known or suspected chronic active Epstein-Barr viral infection (EBV)
- Exclude - * Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- Exclude - * Known history of progressive multifocal leukoencephalopathy (PML)
- Exclude - * Adverse events from prior anti-cancer therapy that have not resolved
  to Grade 1 or better
- Exclude - * Administration of a live, attenuated vaccine within 4 weeks before first
  study treatment administration or anticipation that such a live, attenuated vaccine
  will be required during the study
- Exclude - * Prior solid organ transplantation or allogenic stem cell transplant
- Exclude - * Eligibility for stem cell transplantation (SCT)
- Exclude - * Active autoimmune disease requiring treatment
- Exclude - * Prior treatment with systemic immunosuppressive medications within 2
  weeks or five half-lives (whichever is shorter) prior to the first dose of study
  treatment
- Exclude - * Corticosteroid therapy within 2 weeks prior to first dose of study treatment
- Exclude - * Recent major surgery (within 4 weeks before the first study treatment)
  other than for diagnosis
- Exclude - * Clinically significant history of cirrhotic liver disease
short_title: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice
  in Participants With Relapsed/Refractory Mantle Cell Lymphoma
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Hoffmann-La Roche
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to evaluate the efficacy of glofitamab monotherapy
  compared with an investigator's choice of either rituximab plus bendamustine (BR),
  or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R)
  mantle cell lymphoma (MCL).
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Glofitamab monotherapy
      arm_internal_id: 0
      arm_description: Participants will receive two intravenous (IV) obinutuzumab
        pretreatments prior to receiving IV glofitamab for 12 cycles (cycle length
        = 21 days).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Obinutuzumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Glofitamab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Tocilizumab'
        level_internal_id: 2
        level_suspended: N
    - arm_code: BR or R-Len
      arm_internal_id: 1
      arm_description: Participants will receive bendamustine + rituximab for up to
        6 cycles (cycle length = 28 days), or rituximab + lenalidomide (cycle length
        = 28 days) until disease progression.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Rituximab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Bendamustine'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Lenalidomide'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Tocilizumab'
        level_internal_id: 3
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Recurrent
          - Refractory
          oncotree_primary_diagnosis: Lymphoid Neoplasm
      - and:
        - or:
          - genomic:
              hugo_symbol: CCND1
              variant_category: Structural Variation
